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Mutant (MT) forms of transthyretin (TTR) cause the most common type of autosomal-dominant hereditary systemic
amyloidosis—familial amyloidotic polyneuropathy (FAP). Until 20 years ago, FAP was thought to be an endemic
disease, but FAP is known to occur worldwide. To date, more than 130 mutations in the TTR gene have been
reported. Genotype-phenotype correlations are seen in FAP, and some variation in clinical presentation is often
observed in individual kindreds with the same mutation and even among family members. Of the pathogenic TTR
mutations, Val30Met was the first to be identified and is the most frequent known mutation found throughout the
world. Studies of patients with FAP amyloidogenic TTR (ATTR) Val30Met documented sensorimotor polyneuropathy,
autonomic dysfunction, heart and kidney failure, gastrointestinal tract (GI) disorders, and other symptoms leading to
death, usually within 10 years of the onset of disease. Diagnosis is sometimes delayed, especially in patients without
a clear family history and typical clinical manifestations, since diagnosis requires various studies and techniques such
as histopathology, genetic testing, and mass spectrometry. For treatment of FAP, liver transplantation (LT) reportedly
halts the progression of clinical manifestations. Exchange of an FAP patient’s diseased liver with a healthy liver
causes MT TTR in the body to be replaced by wild-type (WT) TTR. Although clinical evaluations indicated that
progression of other clinical symptoms such as peripheral neuropathy, GI symptoms, and renal involvement usually
halted after LT in FAP ATTR Val30Met patients, recent studies suggested that LT failed to prevent progression of
cardiac amyloidosis in FAP ATTR Val30Met patients after LT, with this failure reportedly being due to continued
formation of amyloid that derived mainly from WT TTR secreted from the transplanted non-mutant liver graft.
In recent years, many therapeutic strategies have been proposed, and several ongoing therapeutic trials involve,
for example, stabilizers of TTR tetramers (tafamidis and diflunisal) and gene therapies to suppress TTR expression
(antisense methods and use of small interfering RNAs). These novel therapies may prove to prevent progression of FAP.
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Mutant (MT) forms of transthyretin (TTR) cause the
most common type of autosomal-dominant hereditary
systemic amyloidosis—familial amyloidotic polyneurop-
athy (FAP) [1-3]. In recent years, many therapeutic strat-
egies have been proposed, and several therapeutic trials
for FAP are ongoing [4,5]. Here, we review clinical presen-
tation, pathogenesis, diagnostic purpose, and recent ad-
vances in the treatment of this disease.* Correspondence: andoy709@kumamoto-u.ac.jp
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Amyloidosis is a protein conformational disorder charac-
terized by extracellular accumulation of amyloid fibrils
derived from various proteins [6-8]. Thus far, 30 distinct
protein precursors of amyloid fibrils have been identified
as causing different kinds of amyloidosis [9-12]. Depend-
ing on the type of amyloidosis, various factors can be re-
sponsible for protein aggregation.
TTR, a major amyloidogenic protein, is mainly synthe-
sized in the liver [13] but also in the choroid plexuses of
the brain [14], retinal pigment epithelial (RPE) cells of the
eye [15], and α-cells of pancreatic islets [16]. TTR forms a
homotetramer that has a dimer-of-dimers configuration
in the bloodstream and that acts as a plasma transporttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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with vitamin A [17]. The plasma TTR concentration is re-
duced in conditions involving inflammation and protein
malnutrition [18]. TTR causes two kinds of amyloidotic
diseases. One is a hereditary systemic amyloidosis, FAP,
which is induced by MT TTR [1-3]. The other type is se-
nile systemic amyloidosis (SSA), which is an aging-related
sporadic systemic amyloidosis that is induced by wild-type
(WT) TTR [19,20]. Destabilization of TTR tetramers is
widely believed to be a critical step in TTR amyloid for-
mation (Figure 1) [21].
FAP
Until 20 years ago, FAP was believed to be a disease that
was restricted to an endemic presence in those specific
areas. However, progress in biochemical and molecular
genetic analyses resulted in an understanding that this
disease now occurs worldwide. To date, more than 130
mutations in the TTR gene have been reported [2,22]. Al-
though 15 TTR mutations are nonamyloidogenic, other
TTR mutations induce systemic amyloidosis, which can
be classified into several phenotypes including peripheral
neuropathy dominant type, commonly called FAP; cardio-
myopathy dominant type, also known as familial amyloi-
dotic cardiomyopathy; vitreous opacity dominant type,
which is thought to be derived mainly from TTR synthe-
sized from RPE cells; and leptomeningeal amyloidosis
dominant type, which is believed to be derived mainly
from the choroid plexuses of the brain and causes central
nervous symptoms. Hereditary TTR amyloidosis mani-
fests genotype-phenotype correlations [2,23,24], and some
variation in clinical presentation is often observed in indi-
vidual kindreds with the same mutation and even among
family members. Of the pathogenic TTR mutations,
Val30Met was the first to be identified and is the bestFigure 1 TTR amyloid formation and therapies for FAP.known mutation found throughout the world, although
the reason for this distribution is not known.
In Japan, Araki et al. first reported a group of patients
with FAP ATTR Val30Met in Kumamoto [22]. Sensori-
motor polyneuropathy, autonomic dysfunction, heart
and kidney failure, gastrointestinal (GI) tract disorders,
and other symptoms (Figure 2) that led to death, usually
within 10 years of the onset of disease, have been do-
cumented in patients with FAP ATTR Val30Met [1]. In
addition to the two endemic foci that were identified in
Japan, many other FAP kindreds with TTR Val30Met
and other mutations were found in Japan (Figure 3).
That phenotypic differences exist among patients with
the same Val30Met mutation and depend on geographic
origin is well known [3,25-27]. Families originating from
Portugal and two endemic areas in Japan (Arao city in
Kumamoto Prefecture and Ogawa village in Nagano
Prefecture) usually have early-onset and high-penetrance
FAP, whereas other Japanese kindreds and Swedish families
evidence late-onset and low-penetrance FAP [3,25-27]. Re-
cent studies reported that certain Swedish patients with
late-onset FAP ATTR Val30Met have amyloid deposits
containing truncated TTR [28-31], which is usually found
in SSA, a sporadic form of TTR amyloidosis [28,32]. Mor-
phological ultrastructural studies showed that amyloid
fibrils in those cases were tightly packed, haphazardly ar-
ranged, and fairly short compared with fibrils from other
FAP ATTR Val30Met patients, usually with early-onset dis-
ease, who did not have truncated TTR in amyloid deposits
[28]. The specific functional and pathological roles of trun-
cated TTR remain to be determined, however.
SSA
SSA, in which WT TTR forms amyloid deposits in various
tissues, is an age-related nonhereditary systemic amyloidosis
Figure 2 Clinical manifestations in FAP ATTR Val30Met patients. (A, B) Amyloid deposits in the sciatic nerve. (A) Congo red staining.
(B) Polarized light. Scale bars: 500 μm.
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[19,20,33-35]. Postmortem studies demonstrated that the
prevalence of SSA was 12–25% in patients older than
80 years [19,20]. Furthermore, recent studies determined
that WT TTR amyloid may also cause several other disor-
ders and conditions [12], such as radiculomyelopathy [36],
tongue necrosis [37], hematuria [38], nodular amyloid de-
posits in the lung [39], and frequent amyloid deposition in
ligaments and tendons such as carpal tunnel and spinal
ligaments [40,41], to a degree not previously known. InFigure 3 Distribution of hereditary TTR amyloidosis in Japan.addition to full-length WT TTR, truncated C-terminal
WT TTR fragments starting at positions 46–52 are usu-
ally detected in amyloid deposits obtained from SSA
patients [32,35].
Diagnosis
Effective medical treatment of patients with TTR amyl-
oidosis requires an accurate diagnosis based on various
studies and techniques [42], such as histopathology, gen-
etic testing, and mass spectrometry (Figure 4). Although
diagnosis in the early stage of FAP is absolutely impera-
tive for proper treatment, the diagnosis is sometimes
delayed, especially in patients without a clear family
history and typical clinical manifestations of FAP [43,44].
Histopathological examinations play a critical role in
obtaining direct evidence of amyloid deposits and deter-
mining the type of amyloid-causing protein [45]. Sys-
temic amyloidosis including FAP is usually diagnosed on
the basis of biopsies of several tissue sites, such as sub-
cutaneous adipose tissue of the abdominal wall [46], GI
tract [47,48], and labial salivary gland [49], because biop-
sies of tissue sites with main clinical symptoms such as
peripheral nerves, heart, and kidney are more invasive.
Biopsy specimens are subjected to Congo red staining to
detect amyloid deposits and are viewed with a micro-
scope under polarized light. In patients with only a small
amount of amyloid deposition, a confirmed diagnosis may
require repeated biopsies. Most often, immunohistochem-
ical determination of the chemical composition of amyloid
Figure 4 Diagnostic studies for FAP. (A-C) Histopathological images of a biopsy specimen of the duodenum obtained from an FAP ATTR
Val30Met patient. (A) Congo red staining. (B) Polarized light. (C) Immunohistochemistry with an anti-TTR antibody. (D) Sequence analysis of the
TTR gene. (E) SELDI-TOF MS analyses of serum TTR from an FAP ATTR Val30Met patient. The molecular weight of MT TTR is 32m/z higher than
that of WT TTR.
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of antibodies recognizing different amyloid types is used
to reveal the origin of deposited protein [50,51]. However,
misdiagnoses have occurred in some cases, especially
when immunohistochemical staining is performed in the
absence of standardized antibodies and appropriate posi-
tive controls [52]. Extraction of amyloid fibril proteins
from frozen and formalin-fixed tissues or from amyloid-
containing histopathological tissue sections followed by
immunostaining or amino acid sequence analyses is an-
other useful way to characterize amyloid deposits [53,54],
especially when immunohistochemical data are negative
or inconclusive. A novel rapid test to determine the type
of amyloidosis based on tandem mass spectrometric ana-
lysis, with specific sampling of clinical biopsy specimens
by means of laser microdissection, was recently reported
[55,56]. With this method, the authors successfully identifiedthe amyloid proteins and classified the types of amyloid-
osis including TTR amyloidosis [39,57]. This method may
be a useful clinical tool for aiding the accurate typing of
amyloidosis.
To obtain accurate results for the TTR mutation in
FAP patients or carriers of variant TTR genes, both
genetic and proteomic methods should be applied to
compensate for the disadvantages and possible pitfalls
of each technique (Figure 4). Mass spectrometric ana-
lysis allows detection of variant TTRs in serum, be-
cause an amino acid substitution results in a change in
the molecular weight of TTR circulating in the bloodstream
[58-60]. We recently applied surface-enhanced laser
desorption/ionization time-of-flight mass spectrometry
(SELDI-TOF MS) to rapid detection of variant TTR in a
patient’s serum [61]. This technique allows the analysis of
a variant form of TTR in a one-step procedure.
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The sections that follow provide details of conventional
and potential treatments of TTR amyloidosis (Figure 1).
Liver transplantation
With regard to treatment of FAP, liver transplantation
(LT) has reportedly halted the progression of clinical
manifestations [62,63]. Exchange of an FAP patient’s dis-
eased liver with a healthy liver causes MT TTR in the
body to be replaced by WT TTR, except for cerebro-
spinal fluid and eyes, into which MT TTR is secreted
from the choroid plexus and the retina, respectively,
even after LT [64,65]. Since 1990, FAP patients have
undergone LT as FAP treatment [66,67]. According to
data in the FAP World Transplant Registry [66], ap-
proximately 120 orthotopic LTs are performed world-
wide each year. LT reportedly prolonged the survival of
FAP ATTR Val30Met patients who were carefully se-
lected for the procedure [68,69]. The modified body
mass index, disease duration, age, type of TTR mutation,
and degree of cardiac involvement are thought to be im-
portant prognostic factors for the disease course after LT
[62,67,69]. The survival rate of FAP ATTR non-Val30Met
patients after LT was reportedly less than that of FAP
ATTR Val30Met patients after LT [66,70,71]. LT could be
less effective for the patients with ATTR non-Val30Met
who have cardiomyopathy or leptomeningeal dominant
symptoms.
Our criteria for performing LT for FAP patients were
as follows: age younger than 60 years, duration of disease
from onset <5 years, creatinine clearance >70 ml/min,
modified body mass index >500, no cardiomegaly, and no
gait disturbance [72]. The main causes of death in patients
after orthotopic LTs involved cardiac problems (24%), sep-
sis (23%), and liver-related complications (14%) [66,70,71].
Although clinical evaluations indicated that progression of
other clinical symptoms such as peripheral neuropathy
[73,74], GI symptoms [75], and renal involvement [72,76]
usually stopped after LT in FAP ATTR Val30Met patients,
other studies suggested that LT failed to prevent progres-
sion of cardiac amyloidosis in FAP ATTR Val30Met pa-
tients after LT [69,77], with this failure reportedly being
due to continued formation of amyloid mainly derived
from WT TTR secreted from the transplanted normal
liver graft [29,30,78]. However, why WT TTR amyloid de-
posits, which are usually found in elderly people with
SSA, occur in some tissue sites of FAP patients after LT
remains to be clarified. It may be that older amyloid de-
posits formed by MT TTR before LT may act as a nidus,
which is well known to enhance polymerization of proteins
[79], and that additional WT TTR amyloid fibrils may
form because of nucleation-dependent polymerization
after LT, although TTR amyloid formation in vitro report-
edly did not depend on nucleation [80].Because of the shortage of livers for transplantation to
patients with malignant or end-stage liver diseases, the
method of using sequential LT with resected livers from
FAP patients was developed [81]. Some patients who
underwent sequential LT with livers from FAP patients
reportedly started to evidence TTR amyloid deposits less
than 10 years after the surgery [82-84]. However, we do
not know whether all such second recipients will eventu-
ally have symptoms of FAP.
Stabilizers of TTR tetramers: tafamidis and diflunisal
The working hypothesis of amyloid formation estab-
lished by a substantial number of studies led to the idea
that stabilizing tetrameric TTR would be a promising
method to prevent amyloid formation [85]. Tetrameric
TTR itself is thought to be nonamyloidogenic, but dis-
sociation of the tetramer into compact non-native
monomers with low conformational stability can lead to
amyloid fibril formation [86]. Baures et al. reported that,
on the basis of in vitro experiments, various nonsteroidal
anti-inflammatory drugs have potential for stabilizing
tetrameric TTR [87]. These efforts thoroughly established
this possibility of stabilization of the tetrameric form of
TTR as a therapeutic strategy.
Two drugs—tafamidis, which is a novel TTR stabilizer,
and diflunisal, which is a nonsteroidal anti-inflammatory
drug developed in 1971 and can stabilize TTR tetramers—
are undergoing clinical development throughout the world.
Tafamidis, a potent and selective stabilizer of tetrameric
TTR, has been approved in Europe and Japan for treat-
ment of adult FAP patients with early symptomatic poly-
neuropathy to delay neurological impairment [88,89]. In
the clinical trial, patients treated with tafamidis had less
neurological deterioration than patients who began tafami-
dis later; they had some preservation of function as mea-
sured by the Neuropathy Impairment Score-Lower Limb
[88,89]. Recently, Berk et al. also reported that diflunisal
reduced the rate of progression of neurological impair-
ment and preserved quality of life [90]. Therapeutic effects
of those TTR stabilizers on long-term outcomes, cardiac
functions and ophthalmic symptom remain to be eluci-
dated. Moreover, a number of structurally diverse small
molecules that bind to TTR, increase its stability, and
thereafter inhibit amyloid fibrillogenesis have been tested.
Gene therapies to suppress TTR expression
Knowledge gained by using LT as therapy for FAP sug-
gested that inhibition of amyloidogenic TTR may prevent
progression of the disease. Antisense methods and small
interfering RNAs (siRNAs) are effective gene-silencing
tools. The antisense oligonucleotides (ASO), which were
recognized as a therapeutic tool in the 1970s, cause
enzymatic degradation of mRNA. RNA interference,
first discovered in Caenorhabditis elegans, is sequence-
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gene expression has also been inhibited by RNA interfer-
ence in mammalian cells by skipping the Dicer step [92].
These methods should be powerful tools for FAP gene
therapy.
Early studies in this field aimed to selectively inhibit
production of MT TTR. Different kinds of siRNA select-
ively silenced TTR gene expression both in vitro and
in vivo [93]. Recently developed siRNA and ASO therap-
ies, however, inhibit both MT TTR and WT TTR
[94,95], because WT TTR also contributes to the forma-
tion of amyloid in FAP, especially after LT. Benson et al.
demonstrated that ASO suppressed TTR mRNA levels in
the liver and in the choroid plexus of the brain [96,97].
Researchers completed a phase I study evaluating the
safety and activity of ASO in healthy volunteers [95]. ASO
reduced plasma TTR protein levels up to 80% without
causing clinically significant adverse reactions. A phase II/
III study evaluating the efficacy of ASO in patients with
FAP is ongoing in 2014. Also, a phase I clinical study with
siRNA for FAP was completed [94], and a phase II/III
study is ongoing in 2014.
Retinal laser photocoagulation
Even after LT, ocular complications have reportedly per-
sisted and worsened, because RPE cells of the eye con-
tinued to synthesize MT TTR in FAP patients [64,98].
To suppress TTR synthesis and ocular symptoms, we
have evaluated retinal laser photocoagulation. This oper-
ation, which is commonly used to treat many retinal dis-
eases, damages the retinal pigment epithelium, the main
location of synthesis of ATTR in ocular tissues. To date,
we discovered that retinal laser photocoagulation clearly
prevented progression of amyloid deposition in the vitre-
ous and on the retinal surface in certain FAP patients,
without causing any adverse effects [99]. Retinal laser
photocoagulation may thus be a new procedure for miti-
gating ocular manifestations in FAP patients.
4′-Iodo-4′-deoxydoxorubicin, doxycycline,
tauroursodeoxycholic acid, and cyclodextrin
Other candidate therapeutic compounds, including 4′-
iodo-4′-deoxydoxorubicin (IDOX), doxycycline, taurour-
sodeoxycholic acid (TUDCA), and cyclodextrin (CyD),
have also been studied.
Merlini et al. first reported IDOX as an agent that
would bind to amyloid fibrils found in five different
types of amyloidosis [100]. Sebastiao et al., in an in vitro
study, noted the interaction of IDOX and ATTR Leu55-
Pro and reported the rapid dissociation of monoclinic
ATTR Leu55Pro crystals soaked with IDOX [101].
Doxycycline influences many functions of mammalian
cells such as proliferation, migration, apoptosis, and matrix
remodeling [102]. Cardoso and colleagues investigated theeffects of doxycycline treatment in vivo by using ATTR
Val30Met transgenic mice [103,104].
TUDCA is a unique natural compound that is a potent
antiapoptotic and antioxidant agent, as it reduces cytotox-
icity in a number of neurodegenerative diseases. Macedo et
al. studied the possible therapeutic application of TUDCA
in FAP [105] and found that TUDCA treatment signifi-
cantly decreased the amount of TTR toxic aggregates.
CyDs are cyclic oligosaccharides composed of 6–8 glu-
cose units [106]. Because CyDs contain a central hydro-
phobic cavity, which can serve as an inclusion site for
hydrophobic molecules, CyDs are now used as multi-
functional drug carriers [107]. Jono et al. reported that
6-O-α-(4-O-α-D-glucuronyl)-D-glucosyl-β-CyD (GUG-β-
CyD), a branched β-CyD derivative, may inhibit TTR mis-
folding by stabilizing the conformation of TTR by means
of interacting with hydrophobic amino acids, especially
the Trp residue of TTR, which thereby suppresses TTR
amyloid formation [108]. CyDs are safe and already widely
used in many fields, especially pharmaceuticals, so GUG-
β-CyD may become a curative drug for TTR amyloidosis.
Gene conversion therapy
As described above, LT was originally suggested as a treat-
ment that would halt production of variant TTR in the
liver. Most FAP symptoms do not progress after LT, when
the MT TTR gene is replaced by the WT TTR gene in the
liver. This finding led to the suggestion that gene therapy
to correct the TTR gene mutation may ameliorate the
clinical symptoms of FAP. Nakamura et al. demonstrated
gene conversion by single-stranded oligonucleotides in
rabbit eyes expressing rabbit WT TTR and in transgenic
murine liver in which the intrinsic WT TTR gene was re-
placed by a TTR Val30Met gene [109].
Immunotherapies
Immunotherapies are also major candidates for TTR
amyloidosis treatment. Gustavsson et al. used various
antigenic mapping methods to find out whether major
antigenic sites differed for normal TTR, ATTR, and in
situ amyloid fibrils [110]. Their data suggested that anti-
genic sites on normal plasma TTR included the AB and
CD loops, with the associated amino acid sequences oc-
curring on the outside of the TTR molecule. An antiserum
against β-strand H (anti-TTR115-124), which estab-
lishes the dimer’s monomer-to-monomer interaction
areas, reacted with only ATTR in amyloid fibrils, not with
normal TTR in plasma. These findings suggested an al-
tered TTR configuration in amyloid fibrils compared with
the TTR configuration in plasma. Thus, anti-TTR115-124,
which seems to be amyloid specific, may be valuable as a
probe and in antibody therapies.
An MT TTR Tyr78Phe that was designed to destabilize the
native structure of TTR tetramer has exposed a cryptotope
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amyloid fibrils or with highly amyloidogenic MTs that
present the amyloid fold [111]. Terazaki et al. demon-
strated that immunization with TTR Tyr78Phe effectively
reduced TTR deposition and cleared amyloid deposits in
an FAP rodent model transgenic for human TTR Val30-
Met with amyloid deposition in the GI tract [112]. This
therapy may be applied to FAP ATTR Val30Met patients
with amyloid deposition in tissues. In addition, this treat-
ment may be useful for vaccination of healthy variant
TTR gene carriers to prevent TTR amyloid deposition in
tissues.
Serum amyloid P component (SAP) is a major compo-
nent of amyloid deposits in all types of amyloidoses. Re-
cently, Bodin, et al. investigated therapeutic effects of
anti-human SAP antibodies on AA amyloid deposition
using a human SAP transgenic mouse model [113]. The
antibodies removed AA amyloid deposits in the mouse
model. This antibody therapy might be applicable to FAP.
Conclusions
Although LT and TTR stabilizers became practical treat-
ments for FAP, there remain many clinical issues we
have to improve. Several clinical trials using other new
methods are ongoing. These novel therapies may prove
to prevent progression of FAP.
Abbreviations
ASO: Antisense oligonucleotides; ATTR: Amyloidogenic TTR; FAP: Familial
amyloidotic polyneuropathy; GI: Gastrointestinal; GUG-β-CyD: 6-O-α-(4-O-α-D-
glucuronyl)-D-glucosyl-β-CyD; IDOX: 4′-iodo-4′-deoxydoxorubicin; LT: Liver
transplantation; MT: Mutant; RPE: Retinal pigment epithelial; SELDI-TOF
MS: Surface-enhanced laser desorption/ionization time-of-flight mass
spectrometry; siRNAs: Small interfering RNAs; SSA: Senile systemic amyloidosis;
TTR: Transthyretin; TUDCA: Tauroursodeoxycholic acid; WT: Wild-type.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MU and YA drafted and revised the manuscript. Both authors read and
approved the final manuscript.
Acknowledgement
We are indebted to Ms. Judith B. Gandy for editorial preparation of the
manuscript. This research was supported by Grants-in-Aid for Science
Research from the Ministry of Education, Culture, Sports, Science and
Technology of Japan (numbers 17390254, 2196354).
Author details
1Department of Diagnostic Medicine, Graduate School of Medical Sciences,
Kumamoto University, 1-1-1 Honjo, 860-0811 Kumamoto, Japan.
2Department of Neurology, Graduate School of Medical Sciences, Kumamoto
University, 1-1-1 Honjo, 860-0811 Kumamoto, Japan.
Received: 9 June 2014 Accepted: 10 September 2014
Published: 13 September 2014
References
1. Ando Y, Nakamura M, Araki S: Transthyretin-related familial amyloidotic
polyneuropathy. Arch Neurol 2005, 62:1057–1062.
2. Zeldenrust S, Benson MD: Familial and senile amyloidosis caused by
transthyretin. In Protein Misfolding Diseases: Current and Emerging Principlesand Therapies. Edited by Alvarado M, Kelly JW, Dobson CM. Hoboken, NJ:
John Wiley & Sons; 2010:795–815.
3. Planté-Bordeneuve V, Said G: Familial amyloid polyneuropathy. Lancet Neurol
2011, 10:1086–1097.
4. Ando Y, Ueda M: Diagnosis and therapeutic approaches to transthyretin
amyloidosis. Curr Med Chem 2012, 19:2312–2323.
5. Ando Y: Liver transplantation and new therapeutic approaches for
familial amyloidotic polyneuropathy (FAP). Med Mol Morphol 2005,
38:142–154.
6. Merlini G, Westermark P: The systemic amyloidoses: clearer understanding
of the molecular mechanisms offers hope for more effective therapies.
J Intern Med 2004, 255:159–178.
7. Benson MD: Amyloidosis in arthritis and allied conditions. In A Textbook of
Rheumatology. Edited by Koopman WJ. Philadelphia: Lippincott Williams &
Wilkins; 2001:1866–1895.
8. Sipe JD, Cohen AS: Review: history of the amyloid fibril. J Struct Biol 2000,
130:88–98.
9. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ,
Westermark P, Nomenclature Committee of the International Society of
Amyloidosis: Amyloid fibril protein nomenclature: 2012
recommendations from the Nomenclature Committee of the
International Society of Amyloidosis. Amyloid 2012, 19:167–170.
10. Westermark P: Aspect of the history and nomenclature of amyloid and
amyloidosis. In Amyloid and Related Disorders: Surgical Pathology and Clinical
Correlations, Current Clinical Pathology. Edited by Picken MM, Dogan A,
Herrera GA. New York: Springer Science + Business Media; 2012:3–8.
11. Benson MD: The hereditary amyloidoses. In Amyloid and Related Disorders:
Surgical Pathology and Clinical Correlations, Current Clinical Pathology. Edited
by Picken MM, Dogan A, Herrera GA. New York: Springer Science + Business
Media; 2012:53–67.
12. Westermark P, Picken MM, Dogan A, Herrera GA: Localized amyloidoses
and amyloidoses associated with aging outside the central nervous
system. In Amyloid and Related Disorders: Surgical Pathology and Clinical
Correlations, Current Clinical Pathology. New York: Springer Science +
Business Media; 2012:81–103.
13. Richardson SJ: TTR synthesis during development and evolution: what
the marsupials revealed. In Recent Advances in Transthyretin Evolution,
Structure and Biological Functions. Edited by Richardson SJ, Cody V.
Heidelberg: Springer; 2009:173–189.
14. Dickson PW, Schreiber G: High levels of messenger RNA for transthyretin
(prealbumin) in human choroid plexus. Neurosci Lett 1986, 66:311–315.
15. Ong DE, Davis JT, O’Day WT, Bok D: Synthesis and secretion of
retinol-binding protein and transthyretin by cultured retinal pigment
epithelium. Biochemistry 1994, 33:1835–1842.
16. Westermark GT, Westermark P: Transthyretin and amyloid in the islets of
Langerhans in type-2 diabetes. Exp Diabetes Res 2008, 2008:429274.
17. Zanotti G, Berni R: Plasma retinol-binding protein: structure and interactions
with retinol, retinoids, and transthyretin. Vitam Horm 2004, 69:271–295.
18. Myron Johnson A, Merlini G, Sheldon J, Ichihara K: Clinical indications for
plasma protein assays: transthyretin (prealbumin) in inflammation and
malnutrition. Clin Chem Lab Med 2007, 45:419–426.
19. Westermark P, Bergström J, Solomon A, Murphy C, Sletten K: Transthyretin-
derived senile systemic amyloidosis: clinicopathologic and structural
considerations. Amyloid 2003, 10:48–54.
20. Ueda M, Horibata Y, Shono M, Misumi Y, Oshima T, Su Y, Tasaki M, Shinriki
S, Kawahara S, Jono H, Obayashi K, Ogawa H, Ando Y: Clinicopathological
features of senile systemic amyloidosis: an ante- and post-mortem study.
Mod Pathol 2011, 24:1533–1544.
21. Lai Z, Colón W, Kelly JW: The acid-mediated denaturation pathway of
transthyretin yields a conformational intermediate that can self-
assemble into amyloid. Biochemistry 1996, 35:6470–6482.
22. Araki S, Mawatari S, Ohta M, Nakajima A, Kuroiwa Y: Polyneurotic
amyloidosis in a Japanese family. Arch Neurol 1968, 18:593–602.
23. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE: Tabulation of
human transthyretin (TTR) variants, 2003. Amyloid 2003, 10:160–184.
24. Mutations in Hereditary Amyloidosis. [http://amyloidosismutations.com/
attr.html]
25. Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, Yamamoto M,
Hattori N, Sobue G, Study Group for Hereditary Neuropathy in Japan: Type I
(transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs
late-onset form. Arch Neurol 2002, 59:1771–1776.
Ueda and Ando Translational Neurodegeneration 2014, 3:19 Page 8 of 10
http://www.translationalneurodegeneration.com/content/3/1/1926. Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M,
Fujitake J, Kawanami T, Kato T, Yamamoto M, Sobue G: Natural history
of transthyretin Val30Met familial amyloid polyneuropathy: analysis
of late-onset cases from non-endemic areas. J Neurol Neurosurg
Psychiatry 2012, 83:152–158.
27. Hellman U, Suhr O: Regional differences and similarities of FAP in
Sweden. Amyloid 2012, 19:53–54.
28. Bergström J, Gustavsson A, Hellman U, Sletten K, Murphy CL, Weiss DT,
Solomon A, Olofsson BO, Westermark P: Amyloid deposits in transthyretin-
derived amyloidosis: cleaved transthyretin is associated with distinct
amyloid morphology. J Pathol 2005, 206:224–232.
29. Ihse E, Suhr OB, Hellman U, Westermark P: Variation in amount of wild-
type transthyretin in different fibril and tissue types in ATTR amyloidosis.
J Mol Med (Berl) 2011, 89:171–180.
30. Oshima T, Kawahara S, Ueda M, Kawakami Y, Tanaka R, Okazaki T, Misumi Y,
Obayashi K, Yamashita T, Ohya Y, Ihse E, Shinriki S, Tasaki M, Jono H,
Asonuma K, Inomata Y, Westermark P, Ando Y: Changes in pathological
and biochemical findings of systemic tissue sites in familial amyloid
polyneuropathy more than 10 years after liver transplantation. J Neurol
Neurosurg Psychiatry 2014, 85:740–746.
31. Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB:
Amyloid fibril composition as a predictor of development of
cardiomyopathy after liver transplantation for hereditary transthyretin
amyloidosis. Transplantation 2012, 93:1017–1023.
32. Westermark P, Sletten K, Johansson B, Cornwell GG 3rd: Fibril in senile
systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad
Sci U S A 1990, 87:2843–2845.
33. Falk RH: Cardiac amyloidosis: a treatable disease, often overlooked.
Circulation 2011, 124:1079–1085.
34. Dubrey SW, Hawkins PN, Falk RH: Amyloid diseases of the heart:
assessment, diagnosis, and referral. Heart 2011, 97:75–84.
35. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P,
Biagini E, Salvi F, Branzi A: Transthyretin-related amyloidoses and the
heart: a clinical overview. Nat Rev Cardiol 2010, 7:398–408.
36. Sueyoshi T, Ueda M, Sei A, Misumi Y, Oshima T, Yamashita T, Obayashi K,
Shinriki S, Jono H, Shono M, Ando Y, Mizuta H: Spinal multifocal
amyloidosis derived from wild-type transthyretin. Amyloid 2011,
18:165–168.
37. Lin JR, Wang H, Collins AB, Stone JR: Tongue necrosis and systemic
vascular amyloidosis. Hum Pathol 2011, 42:734–737.
38. Tirzaman O, Wahner-Roedler DL, Malek RS, Sebo TJ, Li CY, Kyle RA: Primary
localized amyloidosis of the urinary bladder: a case series of 31 patients.
Mayo Clin Proc 2000, 75:1264–1268.
39. Roden AC, Aubry MC, Zhang K, Brady JO, Levin D, Dogan A, Yi ES: Nodular
senile pulmonary amyloidosis: a unique case confirmed by
immunohistochemistry, mass spectrometry, and genetic study. Hum
Pathol 2010, 41:1040–1045.
40. Sueyoshi T, Ueda M, Jono H, Irie H, Sei A, Ide J, Ando Y, Mizuta H: Wild-type
transthyretin-derived amyloidosis in various ligaments and tendons.
Hum Pathol 2011, 42:1259–1264.
41. Sekijima Y, Uchiyama S, Tojo K, Sano K, Shimizu Y, Imaeda T, Hoshii Y, Kato
H, Ikeda S: High prevalence of wild-type transthyretin deposition in
patients with idiopathic carpal tunnel syndrome: a common cause of
carpal tunnel syndrome in the elderly. Hum Pathol 2011, 42:1785–1791.
42. Ando Y, Ueda M: Proteomics for transthyretin (TTR) related amyloidosis.
Curr Proteomics 2011, 8:237–246.
43. Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Tanaka F, Sobue
G: Diagnosis of sporadic transthyretin Val30Met familial amyloid
polyneuropathy: a practical analysis. Amyloid 2011, 18:53–62.
44. Planté-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D,
Said G: Diagnostic pitfalls in sporadic transthyretin familial amyloid
polyneuropathy (TTR-FAP). Neurology 2007, 69:693–698.
45. Grateau G, Stankovic: Diagnosis and classification. In myloidosis: Diagnosis
and Treatment. Edited by Gertz M, Rajkumar SV. New York: Springer Science
+ Business Media; 2010:33–48.
46. Westermark P: Subcutaneous adipose tissue biopsy for amyloid protein
studies. Methods Mol Biol 2012, 849:363–371.
47. Kyle RA, Spencer RJ, Dahlin DC: Value of rectal biopsy in the diagnosis of
primary systemic amyloidosis. Am J Med Sci 1966, 251:501–506.
48. Röcken C, Sletten K: Amyloid in surgical pathology. Virchows Arch 2003,
443:3–16.49. Lechapt-Zalcman E, Authier FJ, Creange A, Voisin MC, Gherardi RK: Labial
salivary gland biopsy for diagnosis of amyloid polyneuropathy.
Muscle Nerve 1999, 22:105–107.
50. Gertz MA: The classification and typing of amyloid deposits. Am J Clin
Pathol 2004, 121:787–789.
51. Murphy CL, Eulitz M, Hrncic R, Sletten K, Westermark P, Williams T, Macy SD,
Wooliver C, Wall J, Weiss DT, Solomon A: Chemical typing of amyloid
protein contained in formalin-fixed paraffin-embedded biopsy
specimens. Am J Clin Pathol 2001, 116:135–142.
52. Linke RP, Oos R, Wiegel NM, Nathrath WB: Classification of amyloidosis:
misdiagnosing by way of incomplete immunohistochemistry and how to
prevent it. Acta Histochem 2006, 108:197–208.
53. Kaplan B, Shtrasburg S, Pras M: Micropurification techniques in the
analysis of amyloid proteins. J Clin Pathol 2003, 56:86–90.
54. Kaplan B, Martin BM, Livneh A, Pras M, Gallo GR: Biochemical subtyping of
amyloid in formalin-fixed tissue samples confirms and supplements
immunohistologic data. Am J Clin Pathol 2004, 121:794–800.
55. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A:
Classification of amyloidosis by laser microdissection and mass
spectrometry-based proteomic analysis in clinical biopsy specimens.
Blood 2009, 114:4957–4959.
56. Dogan A, Picken MM, Dogan A, Herrera GA: Classification of amyloidosis
by mass spectrometry-based proteomics. In Amyloid and Related Disorders:
Surgical Pathology and Clinical Correlations, Current Clinical Pathology. New
York: Springer Science + Business Media; 2012:261–272.
57. Klein CJ, Vrana JA, Theis JD, Dyck PJ, Dyck PJ, Spinner RJ, Mauermann ML,
Bergen HR 3rd, Zeldenrust SR, Dogan A: Mass spectrometric-based
proteomic analysis of amyloid neuropathy type in nerve tissue.
Arch Neurol 2011, 68:195–199.
58. Ando Y, Ohlsson PI, Suhr O, Nyhlin N, Yamashita T, Holmgren G, Danielsson
A, Sandgren O, Uchino M, Ando M: A new simple and rapid screening
method for variant transthyretin-related amyloidosis. Biochem Biophys Res
Commun 1996, 228:480–483.
59. Yamashita T, Ando Y, Bernt Suhr O, Nakamura M, Sakashita N, Ohlsson PI,
Terazaki H, Obayashi K, Uchino M, Ando M: A new diagnostic procedure to
detect unknown transthyretin (TTR) mutations in familial amyloidotic
polyneuropathy (FAP). J Neurol Sci 2000, 173:154–159.
60. Bergquist J, Andersen O, Westman A: Rapid method to characterize
mutations in transthyretin in cerebrospinal fluid from familial
amyloidotic polyneuropathy patients by use of matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry. Clin Chem 2000,
46:1293–1300.
61. Ueda M, Misumi Y, Mizuguchi M, Nakamura M, Yamashita T, Sekijima Y,
Ota K, Shinriki S, Jono H, Ikeda S, Suhr OB, Ando Y: SELDI-TOF mass
spectrometry evaluation of variant transthyretins for diagnosis and
pathogenesis of familial amyloidotic polyneuropathy. Clin Chem 2009,
55:1223–1227.
62. Ericzon G, Lundgren E, Suhr O: Liver transplantation for transthyretin
amyloidosis. In Recent Advances in Transthyretin Evolution, Structure and
Biological Functions. Edited by Richardson SJ, Cody V. Heidelberg: Springer;
2009:239–260.
63. Stangou AJ, Hawkins PN: Liver transplantation in transthyretin-related
familial amyloid polyneuropathy. Curr Opin Neurol 2004, 17:615–620.
64. Ando Y, Terazaki H, Nakamura M, Ando E, Haraoka K, Yamashita T, Ueda M,
Okabe H, Sasaki Y, Tanihara H, Uchino M, Inomata Y: A different amyloid
formation mechanism: de novo oculoleptomeningeal amyloid deposits
after liver transplantation. Transplantation 2004, 77:345–349.
65. Said G, Planté-Bordeneuve V: Familial amyloid polyneuropathy: a clinico-
pathologic study. J Neurol Sci 2009, 284:149–154.
66. Familial Amyloidotic Polyneuropathy World Transplant Registry.
[http://www.fapwtr.org/]
67. Suhr OB, Friman S, Ericzon BG: Early liver transplantation improves familial
amyloidotic polyneuropathy patients’ survival. Amyloid 2005, 12:233–238.
68. Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, Obayashi K,
Nakamura M, Jono H, Shono M, Asonuma K, Inomata Y, Uchino M:
Long-term survival after liver transplantation in patients with familial
amyloid polyneuropathy. Neurology 2012, 78:637–643.
69. Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, Gjertsen H,
Söderdahl G, Wikström L, Ando Y, Suhr OB, Ericzon BG: Liver transplantation
for familial amyloidotic polyneuropathy (FAP): a single-center experience
over 16 years. Am J Transplant 2007, 7:2597–2604.
Ueda and Ando Translational Neurodegeneration 2014, 3:19 Page 9 of 10
http://www.translationalneurodegeneration.com/content/3/1/1970. Wilczek H, Larsson M, Ericzon B: Long-term data from the Familial
Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR).
Amyloid 2011, 18:188–190.
71. Benson MD: Liver transplantation and transthyretin amyloidosis.
Muscle Nerve 2013, 47:157–162.
72. Ohya Y, Okamoto S, Tasaki M, Ueda M, Jono H, Obayashi K, Takeda K, Okajima
H, Asonuma K, Hara R, Tanihara H, Ando Y, Inomata Y: Manifestations of
transthyretin-related familial amyloidotic polyneuropathy: long-term
follow-up of Japanese patients after liver transplantation. Surg Today 2011,
41:1211–1218.
73. Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa PM, Feray C,
Planté V, Ducot B, Ichai P, Lacroix C, Metral S, Bismuth H, Said G: The course
and prognostic factors of familial amyloid polyneuropathy after liver
transplantation. Brain 2000, 123:1495–1504.
74. de Carvalho M, Conceição I, Bentes C, Luís ML: Long-term quantitative
evaluation of liver transplantation in familial amyloid polyneuropathy
(Portuguese V30M). Amyloid 2002, 9:126–133.
75. Suhr OB, Anan I, Ahlström KR, Rydh A: Gastric emptying before and after
liver transplantation for familial amyloidotic polyneuropathy, Portuguese
type (Val30Met). Amyloid 2003, 10:121–126.
76. Nowak G, Suhr OB, Wikström L, Wilczek H, Ericzon BG: The long-term
impact of liver transplantation on kidney function in familial amyloidotic
polyneuropathy patients. Transpl Int 2005, 18:111–115.
77. Hörnsten R, Wiklund U, Olofsson BO, Jensen SM, Suhr OB: Liver
transplantation does not prevent the development of life-threatening
arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type
(ATTR Val30Met) patients. Transplantation 2004, 78:112–116.
78. Liepnieks JJ, Benson MD: Progression of cardiac amyloid deposition in
hereditary transthyretin amyloidosis patients after liver transplantation.
Amyloid 2007, 14:277–282.
79. Morris AM, Watzky MA, Finke RG: Protein aggregation kinetics, mechanism,
and curve-fitting: a review of the literature. Biochim Biophys Acta 2009,
1794:375–397.
80. Hurshman AR, White JT, Powers ET, Kelly JW: Transthyretin aggregation
under partially denaturing conditions is a downhill polymerization.
Biochemistry 2004, 43:7365–7381.
81. Monteiro E, Perdigoto R, Furtado AL: Liver transplantation for familial
amyloid polyneuropathy. Hepatogastroenterology 1998, 45:1375–1380.
82. Stangou AJ, Heaton ND, Hawkins PN: Transmission of systemic
transthyretin amyloidosis by means of domino liver transplantation.
N Engl J Med 2005, 352:2356.
83. Goto T, Yamashita T, Ueda M, Ohshima S, Yoneyama K, Nakamura M, Nanjo
H, Asonuma K, Inomata Y, Watanabe S, Uchino M, Tanaka K, Ando Y:
Iatrogenic amyloid neuropathy in a Japanese patient after sequential
liver transplantation. Am J Transplant 2006, 6:2512–2515.
84. Takei Y, Gono T, Yazaki M, Ikeda S, Ikegami T, Hashikura Y, Miyagawa S,
Hoshii Y: Transthyretin-derived amyloid deposition on the gastric
mucosa in domino recipients of familial amyloid polyneuropathy liver.
Liver Transpl 2007, 13:215–218.
85. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW: The transthyretin
amyloidoses: from delineating the molecular mechanism of aggregation
linked to pathology to a regulatory-agency-approved drug. J Mol Biol
2012, 421:185–203.
86. Quintas A, Saraiva MJ, Brito RM: The tetrameric protein transthyretin
dissociates to a non-native monomer in solution. A novel model for
amyloidogenesis. J Biol Chem 1999, 274:32943–32949.
87. Baures PW, Oza VB, Peterson SA, Kelly JW: Synthesis and evaluation of
inhibitors of transthyretin amyloid formation based on the non-steroidal
anti-inflammatory drug, flufenamic acid. Bioorg Med Chem 1999, 7:1339–1347.
88. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-
Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt
HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A,
Grogan DR: Tafamidis for transthyretin familial amyloid polyneuropathy:
a randomized, controlled trial. Neurology 2012, 79:785–792.
89. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB,
Conceiçao I, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J,
Packman J, Grogan DR: Long-term effects of tafamidis for the
treatment of transthyretin familial amyloid polyneuropathy. J Neurol
2013, 260:2802–2814.
90. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan
MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A,Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S,
Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ, Diflunisal Trial Consortium:
Repurposing diflunisal for familial amyloid polyneuropathy: a randomized
clinical trial. JAMA 2013, 310:2658–2667.
91. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and
specific genetic interference by double-stranded RNA in Caenorhabditis
elegans. Nature 1998, 391:806–811.
92. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes
of 21-nucleotide RNAs mediate RNA interference in cultured mammalian
cells. Nature 2001, 411:494–498.
93. Kurosawa T, Igarashi S, Nishizawa M, Onodera O: Selective silencing of a
mutant transthyretin allele by small interfering RNAs. Biochem Biophys Res
Commun 2005, 337:1012–1018.
94. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa
J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J,
Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland
T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur
SV, Vaishnaw AK, Sah DW, Gollob JA, et al: Safety and efficacy of RNAi
therapy for transthyretin amyloidosis. N Engl J Med 2013, 369:819–829.
95. Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP:
Clinical development of an antisense therapy for the treatment of
transthyretin-associated polyneuropathy. Amyloid 2012, 19:43–44.
96. Benson MD, Kluve-Beckerman B, Zeldenrust SR: Targeted suppression
of an amyloidogenic transthyretin with antisense oligonucleotides.
Muscle Nerve 2006, 33:609–618.
97. Benson MD, Smith RA, Hung G, Kluve-Beckerman B, Showalter AD, Sloop
KW, Monia BP: Suppression of choroid plexus transthyretin levels by
antisense oligonucleotide treatment. Amyloid 2010, 17:43–49.
98. Haraoka K, Ando Y, Ando E, Sun X, Nakamura M, Terazaki H, Misumi S,
Tanoue Y, Tajiri T, Shoji S, Ishizaki T, Okabe H, Tanihara H: Presence of
variant transthyretin in aqueous humor of a patient with familial
amyloidotic polyneuropathy after liver transplantation. Amyloid 2002,
9:247–251.
99. Kawaji T, Ando Y, Hara R, Tanihara H: Novel therapy for transthyretin-related
ocular amyloidosis: a pilot study of retinal laser photocoagulation.
Ophthalmology 2010, 117:552–555.
100. Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, Ferrari M,
Zorzoli I, Marinone MG, Garini P, Diegoli M, Trizio D, Ballinari D: Interaction
of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils:
inhibition of amyloidogenesis. Proc Natl Acad Sci U S A 1995, 92:2959–2963.
101. Sebastiao MP, Merlini G, Saraiva MJ, Damas AM: The molecular interaction
of 4′-iodo-4′-deoxydoxorubicin with Leu-55Pro transthyretin ’amyloid-like’
oligomer leading to disaggregation. Biochem J 2000, 351:273–279.
102. Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM: Doxycycline
modulates smooth muscle cell growth, migration, and matrix
remodeling after arterial injury. Am J Pathol 2002, 160:1089–1095.
103. Cardoso I, Merlini G, Saraiva MJ: 4′-Iodo-4′-deoxydoxorubicin and
tetracyclines disrupt transthyretin amyloid fibrils in vitro producing
noncytotoxic species. Screening for TTR fibril disrupters. FASEB J 2003,
17:803–809.
104. Cardoso I, Saraiva MJ: Doxycycline disrupts transthyretin amyloid: evidence
from studies in a FAP transgenic mice model. FASEB J 2006, 20:234–239.
105. Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ: Anti-apoptotic
treatment reduces transthyretin deposition in a transgenic mouse model
of familial amyloidotic polyneuropathy. Biochim Biophys Acta 2008,
1782:517–522.
106. Uekama K, Hirayama F, Irie T: Cyclodextrin drug carrier systems. Chem Rev
1998, 98:2045–2076.
107. Davis ME, Brewster ME: Cyclodextrin-based pharmaceutics: past, present
and future. Nat Rev Drug Discov 2004, 3:1023–1035.
108. Jono H, Anno T, Motoyama K, Misumi Y, Tasaki M, Oshima T, Mori Y,
Mizuguchi M, Ueda M, Shono M, Obayashi K, Arima H, Ando Y:
Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic
transthyretin misfolding in transthyretin-related amyloidosis. Biochem J
2011, 437:35–42.
109. Nakamura M, Ando Y, Nagahara S, Sano A, Ochiya T, Maeda S, Kawaji T,
Ogawa M, Hirata A, Terazaki H, Haraoka K, Tanihara H, Ueda M, Uchino M,
Yamamura K: Targeted conversion of the transthyretin gene in vitro and
in vivo. Gene Ther 2004, 11:838–846.
110. Gustavsson A, Engström U, Westermark P: Mechanisms of transthyretin
amyloidogenesis. Antigenic mapping of transthyretin purified from
Ueda and Ando Translational Neurodegeneration 2014, 3:19 Page 10 of 10
http://www.translationalneurodegeneration.com/content/3/1/19plasma and amyloid fibrils and within in situ tissue localizations. Am J
Pathol 1994, 144:1301–1311.
111. Redondo C, Damas AM, Olofsson A, Lundgren E, Saraiva MJ: Search for
intermediate structures in transthyretin fibrillogenesis: soluble tetrameric
Tyr78Phe TTR expresses a specific epitope present only in amyloid
fibrils. J Mol Biol 2000, 304:461–470.
112. Terazaki H, Ando Y, Fernandes R, Yamamura K, Maeda S, Saraiva MJ:
Immunization in familial amyloidotic polyneuropathy: counteracting
deposition by immunization with a Y78F TTR mutant. Lab Invest 2006,
86:23–31.
113. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA,
Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon
AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M,
Hawkins PN, Pepys MB: Antibodies to human serum amyloid P component
eliminate visceral amyloid deposits. Nature 2010, 468:93–97.
doi:10.1186/2047-9158-3-19
Cite this article as: Ueda and Ando: Recent advances in transthyretin
amyloidosis therapy. Translational Neurodegeneration 2014 3:19.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
